Exchange: NASDAQ·Updated 09:00 AM EDT
ACTU logo

ACTU Actuate Therapeutics Inc.

$1.50
$0.04
(2.60%)
Pre-Market
Prev Close $1.54
EarningsNov 12
Mkt Cap$36.98M
Vol4,520.00

About ACTU

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
43

Bearish Sentiment

How do you feel about ACTU?

Advertisement|Remove ads.